在杜申尼肌肉发育不良的皮质类固醇治疗
1Department of Pediatric Physical Medicine and Rehabilitation, Hôpital Femme, Mère, Enfant, Hospices Civils de Lyon, Bron F-69677 Cedex, France.
概括
皮质类固醇可通过延迟功能损失和减少并发症,显著提高杜申氏肌肉缩 (DMD) 患者的预期寿命. 虽然副作用需要管理,但它们仍然是DMD的主要症状治疗方法.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 杜申肌肉发育不良 (DMD) 是一种严重的,无法治愈的遗传疾病,影响肌肉功能和寿命.
- 多学科护理显著改善了患者的预后和预期寿命.
- 二十多年来,皮质类固醇一直是DMD管理的基石.
研究的目的:
- 审查常规皮质类固醇在杜申氏肌肉发育不良症管理中的确定的作用和疗效.
- 讨论DMD中皮质类固醇治疗的益处,最佳剂量和副作用管理.
- 引入新兴的治疗方法,如瓦摩洛隆和吉文斯塔特,作为潜在的替代品或辅助剂.
主要方法:
- 关于在杜氏肌肉发育不良症中使用皮质类固醇的现有文献的审查.
- 对临床试验数据关于疗效和安全性概况的分析.
- 传统皮质类固醇与新型治疗剂的比较概述.
主要成果:
- 皮质类固醇明显延迟了DMD患者的行走能力丧失和功能衰退.
- 早期启动皮质类固醇可以改善爬楼梯,起床,行走和上肢功能.
- 皮质类固醇可能会延迟呼吸衰竭和心肌病发作,尽管副作用需要仔细监测和管理.
结论:
- 传统的皮质类固醇仍然是杜申肌力发育不良症的标准症状治疗方法,显著改善生活质量并延长存活时间.
- 仔细管理皮质类固醇相关的副作用对于持续的治疗效益至关重要.
- 瓦莫罗隆和吉维诺斯塔特代表了DMD治疗方法的有希望的进步,提供了具有不同疗效和安全性概况的潜在替代品.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
408
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
408
01:26COPD: Management Using Bronchodilators and Corticosteroids
700
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
700
01:21Satellite Stem Cells and Muscular Dystrophy
2.3K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.3K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
01:20Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K